• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Zoetis Inc.

    5/8/24 5:13:27 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZTS alert in real time by email
    DEFA14A 1 tm2413852d2_defa14a.htm DEFA14A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No.     )

     

    Filed by the Registrant  ¨

     

    Filed by a Party other than the Registrant  ¨

     

    Check the appropriate box:

    ¨Preliminary Proxy Statement
    ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ¨Definitive Proxy Statement
    xDefinitive Additional Materials
    ¨Soliciting Material under §240.14a-12

     

    Zoetis Inc
    (Name of Registrant as Specified in Its Charter)
     
      
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

    xNo fee required.
    ¨Fee paid previously with preliminary materials.
    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.

     

     

     

     

     

     

     

     

    SUPPLEMENT NO. 2 TO PROXY STATEMENT
    ANNUAL MEETING OF SHAREHOLDERS
    MAY 22, 2024

     

    May 8, 2024

     

    Dear Fellow Shareholders:

     

    In advance of our 2024 Annual Meeting of Shareholders scheduled for May 22, 2024 (the “2024 Annual Meeting”), I am writing to you once again on behalf of the Board of Directors (the “Board”) of Zoetis Inc. (“Zoetis”) to address a recommendation by proxy advisory firm Institutional Shareholder Services (“ISS”) to vote against Louise M. Parent, director and Chair of our Corporate Governance and Sustainability Committee and to reaffirm the Board’s sincere and longstanding commitment to shareholder accountability and responsiveness.

     

    As noted in our first supplement to the proxy statement dated May 6, 2024 (the “Supplement No. 1”), shareholders voted on two proposals at the 2023 Annual Meeting of Shareholders (the “2023 Annual Meeting”) regarding the adoption of special meeting rights: (i) a management proposal implementing a special meeting right with a 25% threshold and (ii) a shareholder proposal, submitted by John Chevedden, requesting the Board implement a special meeting right with a 10% threshold (the “Chevedden Proposal”).

     

    During the months prior to the 2023 Annual Meeting, we conducted extensive outreach and engagement to our shareholder base with the goal of proactively responding to shareholder expectations on special meeting rights. As noted in Supplement No. 1, our shareholders strongly indicated a preference for a special meeting right with a 25% threshold. Consequently, instead of waiting on the outcome of the Chevedden Proposal, we decided to take the initiative by proposing a special meeting right with a threshold that we believed reflected the majority view of our shareholder base. The vote outcomes on the proposals appeared to support our understanding that our shareholder base strongly preferred a special meeting right with a 25% threshold: over 99% of the votes cast (abstentions excluded) supported the management proposal compared to just over 52% of the votes cast (abstentions excluded) that supported the Chevedden Proposal. Our largest shareholder Vanguard also featured our engagement efforts and responsive actions in their 2023 Annual Report. Following the 2023 Annual Meeting, we did not receive any further shareholder feedback on the matter that suggested further changes were advisable.

     

    ISS has taken the position that our Board has not sufficiently described its engagement with shareholders on special meeting rights following the 2023 Annual Meeting. Specifically, ISS noted that “the number of shareholders it spoke to on the topic, whether any of them actually supported the shareholder proposal, and what their feedback may have been is not provided,” and on this basis recommended shareholders vote against Louise M. Parent as the Chair of the Corporate Governance and Sustainability Committee. Below, we respond to ISS’s feedback and explain why we respectfully disagree with its recommendation. We urge you to support the re-election of our full Board which has been and continues to be focused on serving the best interests of our shareholders.

     

     

     

     

    We Thoughtfully and Proactively Engaged with Shareholders Both Before and After Our 2023 Annual Meeting

     

    We believe in proactively addressing shareholder concerns. It is for these reasons we engaged in extensive outreach prior to our 2023 Annual Meeting to fully understand the perspectives of our shareholders on special meeting rights. Specifically, members of management and the Board, engaged 16 of our largest shareholders, comprising over 30% of our outstanding shares. Shareholders overwhelmingly indicated their preference for a special meeting right with a 25% threshold rather than a 10% threshold. We promptly took responsive action by proposing a special meeting right with a 25% threshold at the 2023 Annual Meeting.

     

    After the conclusion of the 2023 Annual Meeting, we reviewed how our shareholders voted and remained alert to any inbound feedback from our shareholders. We also conducted environmental, social and governance (“ESG”) engagements with eight shareholders, including the largest individual shareholder which voted for the special meeting right with a 10% threshold at the 2023 Annual Meeting. Our Investor Relations team also conducted general investor sessions with a significant number of our shareholders, including 27 out of our top 30 shareholders, representing over 50% of the voting shares. At neither the ESG-focused sessions nor the Investor Relations sessions did we receive any feedback from any of our shareholders that further action needed to be taken on special meeting rights. We also did not receive any other inbound feedback from shareholders expressing concern about our special meeting policy, including from John Chevedden, who submitted a different shareholder proposal for the 2024 Annual Meeting.

     

    Our engagement approach with our shareholders following the 2023 Annual Meeting regarding special meeting rights was informed by the following factors: (i) the fact that we had already conducted extensive and proactive outreach prior to the 2023 Annual Meeting, (ii) the 2023 Annual Meeting vote results, which strongly favored a special meeting right with a 25% threshold, (iii) the continued absence of further shareholder feedback on the issue, (iv) the fact that our special meeting policy currently falls within the expectations of our largest shareholders’ proxy voting policies, and (v) the absence of significant changes to our shareholder base or governance practices that could prompt shareholders to revisit our recently adopted special meeting provision. We also wanted to be considerate and prudent in how we allocated our internal resources and the time of our shareholders when determining the scope and scale of our engagement program, particularly since we had already conducted extensive outreach on special meeting rights only months earlier.

     

    Louise M. Parent and our Board are Strong Advocates of Shareholder Rights and Are Committed to Acting in the Best Interests of Our Shareholders

     

    In just three annual meeting cycles as Chair of the Zoetis Corporate Governance and Sustainability Committee, Ms. Parent, together with the rest of our Board, has driven significant governance changes in service of shareholder interests, including:

     

    -Amending our Charter in 2022 to eliminate supermajority voting provisions

    -Amending our Charter in 2022 to implement a phased-in de-classification of the Board

    -Amending our Charter in 2023 to implement the right for shareholders to call a special meeting with an ownership threshold of 25%

    -Significantly expanding our ESG-related disclosures

     

    2

     

     

    As a Board, we take our responsibilities very seriously and we are committed to ensuring that shareholder perspectives are heard and appropriately addressed. We welcome and encourage shareholder feedback and we value the relationships that we have built with our shareholder over the years.

     

    We Remain Open to Further Shareholder Feedback on Our Governance Practices

     

    As a Board, we have seen governance practices evolve over the years and we very much hope to continue working closely with our shareholders to understand their perspectives. We remain open, as always, to opportunities for improvement in our governance practices and we, as a matter of policy, also review our governance practices periodically to identify appropriate updates.

     

    As a further step to ensure all of our shareholders’ voices have been properly attended to with respect to special meeting rights, we plan to conduct further outreach to our top 30 known shareholders, representing over 50% of our outstanding shares in the coming days to further confirm that our policy remains aligned with their expectations. We will carefully consider any feedback from these engagement sessions and will plan to take further responsive actions, if necessary, to meet the expectations of our shareholders.

     

    ***

     

    In light of the actions that we have taken to date and our track record of responsiveness to our shareholders, we urge all shareholders to vote “FOR” the re-election of all of our directors in Proposal 1, including Louise M. Parent.

     

    Sincerely,

     

    Michael McCallister

     

    Chair of the Board

     

    3

     

    Get the next $ZTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZTS

    DatePrice TargetRatingAnalyst
    1/22/2026$135.00Overweight → Neutral
    Piper Sandler
    12/15/2025$135.00Buy → Neutral
    BofA Securities
    12/9/2025$136.00Equal Weight
    Barclays
    11/21/2025Sector Weight
    KeyBanc Capital Markets
    7/17/2025$155.00Outperform → Market Perform
    Leerink Partners
    6/18/2025$160.00Buy → Hold
    Stifel
    12/2/2024$215.00Outperform
    Leerink Partners
    7/25/2024$220.00Buy
    BTIG Research
    More analyst ratings

    $ZTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Esch Kevin converted options into 93 shares and covered exercise/tax liability with 33 shares, increasing direct ownership by 22% to 327 units (SEC Form 4)

    4 - Zoetis Inc. (0001555280) (Issuer)

    2/10/26 4:32:03 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Vice President Ashton Nicholas converted options into 779 shares and covered exercise/tax liability with 409 shares, increasing direct ownership by 34% to 1,464 units (SEC Form 4)

    4 - Zoetis Inc. (0001555280) (Issuer)

    2/10/26 4:31:57 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Vice President Lagano Roxanne covered exercise/tax liability with 438 shares and converted options into 1,149 shares, increasing direct ownership by 5% to 15,140 units (SEC Form 4)

    4 - Zoetis Inc. (0001555280) (Issuer)

    2/10/26 4:31:51 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zoetis Declares Second Quarter 2026 Dividend

    The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the second quarter of 2026. The dividend will be paid on Tuesday, June 2, 2026, to all holders of record of the Company's common stock as of the close of business on Monday, April 20, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock producers. The com

    2/5/26 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2025 Financial Results

    Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 12, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2025 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay of the webcast will be made available on February 12, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular p

    12/30/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis to Participate in the 44th Annual J.P. Morgan Healthcare Conference

    Zoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 10:30 a.m. PT. Investors and other interested parties can access a live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by ad

    12/18/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zoetis downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Zoetis from Overweight to Neutral and set a new price target of $135.00

    1/22/26 8:26:41 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis downgraded by BofA Securities with a new price target

    BofA Securities downgraded Zoetis from Buy to Neutral and set a new price target of $135.00

    12/15/25 9:58:23 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Zoetis with a new price target

    Barclays initiated coverage of Zoetis with a rating of Equal Weight and set a new price target of $136.00

    12/9/25 8:55:22 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    SEC Filings

    View All

    Zoetis Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Zoetis Inc. (0001555280) (Filer)

    2/5/26 4:22:05 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Zoetis Inc.

    SCHEDULE 13G/A - Zoetis Inc. (0001555280) (Subject)

    1/7/26 2:59:33 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure

    8-K - Zoetis Inc. (0001555280) (Filer)

    12/18/25 4:17:38 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

    For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.  Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o

    1/13/22 10:26:13 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Leadership Updates

    Live Leadership Updates

    View All

    Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

    Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 2026. Dr. Esch currently serves as Senior Vice President of Global Therapeutics at Zoetis and joined Zoe

    11/3/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Appoints Stephanie Tilenius to its Board of Directors

    Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board. Ms. Tilenius is a serial entrepreneur and has founded several healthcare companies, including most recently a stealth company in the longevity AI space. Previously, she founded Vida Health, Inc., a leading B2B chronic care platform focusing on diabetes and obesity, and scaled it nationally for Fortune 500 companies, large payers and healthcar

    10/28/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dr. Mark Stetter Elected to Zoetis Board of Directors

    Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He will serve on the Board's Quality and Innovation Committee. "Dr. Stetter brings invaluab

    5/22/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Financials

    Live finance-specific insights

    View All

    Zoetis Declares Second Quarter 2026 Dividend

    The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the second quarter of 2026. The dividend will be paid on Tuesday, June 2, 2026, to all holders of record of the Company's common stock as of the close of business on Monday, April 20, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock producers. The com

    2/5/26 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2025 Financial Results

    Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 12, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2025 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay of the webcast will be made available on February 12, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular p

    12/30/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Declares First Quarter 2026 Dividend; Board Approves 6% Payment Increase

    The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company's common stock as of the close of business on Tuesday, January 20, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide --

    12/11/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    2/13/24 5:17:36 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    1/26/24 11:49:41 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    2/9/23 11:37:19 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care